| Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. | |
| | |
MedLine Citation:
|
PMID: 11984517 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND & AIMS: Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis has not been established. METHODS: We pooled individual data from 3010 naive patients with pretreatment and posttreatment biopsies from 4 randomized trials. Ten different regimens combining standard interferon, PEG interferon, and ribavirin were compared. The impact of each regimen was estimated by the percentage of patients with at least 1 grade improvement in the necrosis and inflammation (METAVIR score), the percentage of patients with at least 1 stage worsening in fibrosis METAVIR score, and by the fibrosis progression rate per year. RESULTS: Necrosis and inflammation improvement ranged from 39% (interferon 24 weeks) to 73% (optimized PEG 1.5 and ribavirin; P < 0.001). Fibrosis worsening ranges from 23% (interferon 24 weeks) to 8% (optimized PEG 1.5 and ribavirin; P < 0.001). All regimens significantly reduced the fibrosis progression rates in comparison to rates before treatment. The reversal of cirrhosis was observed in 75 patients (49%) of 153 patients with baseline cirrhosis. Six factors were independently associated with the absence of significant fibrosis after treatment: baseline fibrosis stage (odds ratio [OR] = 0.12; P < 0.0001), sustained viral response (OR = 0.36; P < 0.0001), age < 40 years (OR = 0.51; P < 0.001), body mass index < 27 kg/m(2) (OR = 0.65; P < 0.001), no or minimal baseline activity (OR = 0.70; P = 0.02), and viral load < 3.5 millions copies per milliliter (OR = 0.79; P = 0.03). CONCLUSIONS: PEG-interferon and ribavirin combination significantly reduces the rate of fibrosis progression in patients with hepatitis C. |
| | |
Authors:
|
Thierry Poynard; John McHutchison; Michael Manns; Christian Trepo; Karen Lindsay; Zachary Goodman; Mei-Hsiu Ling; Janice Albrecht |
Related Documents
:
|
21257337 - Compartmental tongue surgery: long term oncologic results in the treatment of tongue ca... 9756007 - Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepati... 11951927 - Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cel... 21495027 - Reirradiation for recurrent medulloblastoma. 20595827 - Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction. 3441327 - Strontium kinetics in metastasized prostatic carcinoma: a comparison with the predictio... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Gastroenterology Volume: 122 ISSN: 0016-5085 ISO Abbreviation: Gastroenterology Publication Date: 2002 May |
Date Detail:
|
Created Date: 2002-05-01 Completed Date: 2002-05-23 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0374630 Medline TA: Gastroenterology Country: United States |
Other Details:
|
Languages: eng Pagination: 1303-13 Citation Subset: AIM; IM |
Affiliation:
|
Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, Université Paris VI, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiviral Agents / administration & dosage* Drug Therapy, Combination Hepatitis C, Chronic / drug therapy* Humans Interferon Alfa-2b / administration & dosage* Liver Cirrhosis / drug therapy* Polyethylene Glycols / administration & dosage* Ribavirin / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Polyethylene Glycols; 36791-04-5/Ribavirin; 99210-65-8/Interferon Alfa-2b |
| Comments/Corrections | |
Comment In:
|
Gastroenterology. 2002 May;122(5):1525-8
[PMID:
11984538
]
Z Gastroenterol. 2003 Mar;41(3):271-4 [PMID: 16308928 ] Gastroenterology. 2003 Apr;124(4):1166-7 [PMID: 12671922 ] Gastroenterology. 2003 May;124(5):1561 [PMID: 12760398 ] Gastroenterology. 2003 Jun;124(7):2003-4; author reply 2004-5 [PMID: 12812198 ] Gastroenterology. 2003 Aug;125(2):629-30; author reply 630-31 [PMID: 12891578 ] Gastroenterology. 2003 Feb;124(2):584; author reply 584-5 [PMID: 12557174 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin re...
Next Document: Rehabilitation of swallowing by exercise in tube-fed patients with pharyngeal dysphagia secondary to...